Completed PHASE2 INTERVENTIONAL 2-arm NCT01470599

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

A Open-Label Extension Study Of CP-690,550 As Maintenance Therapy In Patients With Crohn's Disease

Sponsor: Pfizer

Interventions CP-690,550

Updated 9 times since 2017 Last updated: Sep 12, 2017 Started: Apr 30, 2012 Primary completion: Jul 31, 2016 Completion: Jul 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01470599, this PHASE2 trial focuses on Crohn's Disease and remains completed. Sponsored by Pfizer, it has been updated 9 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Oct 2017 — Jun 2018 [monthly]

Completed PHASE2
Mar 2017 — Oct 2017 [monthly]

Completed PHASE2
Feb 2017 — Mar 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Ann Arbor, United States , Barcelona, Spain , Berlin, Germany , Budapest, Hungary , Chiba, Japan , Clayton, Australia , Clearwater, United States , Cleveland, United States , Durban, South Africa and 43 more locations